Table 1.

Participant characteristics at entry for women included in the analyses of the NSABP STAR Trial (P-2)

Participant characteristics	Tamoxifen		Raloxifene
	No.	%	No.	%
Age (years)
≤ 49	884	9.1	878	9.0
50–59	4,856	49.9	4,855	49.8
60–69	3,137	32.2	3,174	32.5
≥ 70	859	8.8	847	8.7
Race/ethnicity
White	9,105	93.5	9,115	93.4
African-American	233	2.4	243	2.5
Hispanic	192	2.0	193	2.0
Other	206	2.1	203	2.1
No. 10 relatives with breast cancer
0	2,838	29.1	2,791	28.6
1	5,046	51.8	5,135	52.6
2	1,532	15.7	1,561	16.0
≥ 3	320	3.3	267	2.7
History of hysterectomy
No	4,739	48.7	4,717	48.4
Yes	4,997	51.3	5,037	51.6
History of lobular carcinoma in situ
No	8,844	90.8	8,865	90.9
Yes	892	9.2	889	9.1
History of breast atypical hyperplasia
No	7,545	77.5	7,513	77.0
Yes	2,191	22.5	2,241	23.0
5-year predicted breast cancer risk (%)*
≤ 2.00	1,055	10.8	1,102	11.3
2.01–3.00	2,993	30.7	2,893	29.7
3.01–5.00	3,042	31.2	3,086	31.6
≥ 5.01	2,646	27.2	2,673	27.4
Total	9,736	100.0	9,754	100.0

Abbreviation: NSABP STAR, National Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene

^*Determined by the Gail model.